8 Best US Stocks Under $10 to Invest in

Published on August 21, 2025 at 2:23 pm by Rameen Kasana in Hedge Funds, News

In this article, we will take a look at some of the best US stocks under $10 to invest in.

Everyone seeks a stock that has good upside potential, but a stock that is cheap and has good prospects – that’s what a steal deal looks like. From leading investors to top analysts, the financial experts have stressed one thing: a cheap price doesn’t always imply the stock’s value.

In recent times, investors have shifted their focus from high-flying tech stocks to more valuable, mispriced companies, aiming to invest in genuine bargains. As Warren Buffett says,

“Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down.”

For instance, a study by Josef Lakonishok, Andrei Shleifer, and Robert Vishny in 1994 highlights that value stocks tend to outperform glamour stocks by substantial margins. Thus, a smart investor is the one who acquires stocks when nobody wants them.

Our Methodology

In compiling a list of the 8 best US stocks under $10 to invest in, we have selected stocks that are favorites among investors. These stocks have positive upside potential and are recommended by research firms. The upside potential is calculated using the one-year price targets by Yahoo Finance and then ranked in ascending order.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

8. Definitive Healthcare Corp. (NASDAQ:DH)

Upside potential as of August 16, 2025: 17.31%

BofA Securities has reaffirmed its Buy rating on Definitive Healthcare Corp. (NASDAQ:DH), while maintaining a price target of $4.50, implying a surge of 16.3%. This move comes as the company reports revenue and EBITDA above the research firm’s estimates and consensus forecasts.

In its latest earnings call, Definitive Healthcare Corp. (NASDAQ:DH) has raised full-year revenue guidance to $237-$240 million owing to better retention. This signals the company’s focus on streamlining its sales force. The management also announced the addition of 12 new enterprise clients within the quarter.

The company’s future looks promising, with analysts emphasizing retention rates, renewal trends, and the impact of operational changes. With strong initiatives in mind, Definitive Healthcare Corp. (NASDAQ:DH) is poised for growth.

Definitive Healthcare Corp. (NASDAQ:DH), headquartered in Massachusetts, is a provider of a SaaS healthcare commercial intelligence platform. Founded in 2011, the company has a well-diversified clientele in the biopharmaceutical, healthcare, and technology industries.

7. Evolv Technologies Holdings, Inc. (NASDAQ:EVLV)

Upside potential as of August 16, 2025: 22.58%

Cantor Fitzgerald analysts have increased the price target on Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) to $9, up from $7, with an unchanged Overweight rating. This move follows the company’s strong quarterly performance, delivering a 29% year-over-year revenue growth.

Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) appears to be in a strong position under new management, outperforming its competitors and transitioning smoothly to a small-cap company with an equally promising future. Having said that, the stock has posted a return of 115% compared to the 16.35% one-year return of the S&P 500 (^GSPC).

The company’s commitment to building a durable and high-growth business with predictable results is what sets it apart from the others. Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) also announced upward guidance during its latest earnings call. With such optimism surrounding the company, there’s no doubt that the investors are gravitating towards the stock.

Evolv Technologies Holdings, Inc. (NASDAQ:EVLV), founded in 2013, is a Massachusetts-based provider of AI weapons detection that aids in artificial intelligence (AI)-based weapons detection. The core offerings of the company include Evolv Express, Evolv Insights Analytics Application, and Evolv eXpedite.

6. Shoals Technologies Group, Inc. (NASDAQ:SHLS)

Upside potential as of August 16, 2025: 38.34%

According to a research note, analysts at Wall Street Zen have upgraded Shoals Technologies Group, Inc. (NASDAQ:SHLS) to “Strong Buy” from “Hold.” This reflects increased investor confidence as the stock has been revised upwards by Roth Capital as well.

Many investors view Shoals Technologies Group, Inc. (NASDAQ:SHLS) as an interesting player in the market with a technology that is difficult to imitate and a backlog that is healthy. We can’t deny that clean and renewable energy is here to stay, and this paints the long-term picture quite optimistically.

What’s quite appealing is the company’s recent strategic initiatives that aim to enhance market share by attracting new customers and regaining old ones. The promotional strategies employed are considered the cause of the company’s declining gross margins, but as soon as the goal is achieved, Shoals Technologies Group, Inc. (NASDAQ:SHLS) will return to its long-term target.

Shoals Technologies Group, Inc. (NASDAQ:SHLS) is a Tennessee-based provider of electrical balance of system (EBOS) solutions and components. Incorporated in 1996, the company offers products utilized by the solar and battery storage industries.

5. National CineMedia, Inc. (NASDAQ:NCMI)

Upside potential as of August 16, 2025: 50.97%

Benchmark has reaffirmed its Buy rating on National CineMedia, Inc. (NASDAQ:NCMI), while maintaining a price target of $7.00, which reflects a potential surge of nearly 59.82% from current levels. This optimism is based on two points: advertising demand and theatrical attendance.

During the recent earnings call, the management highlighted strategic advancements, particularly scaling programmatic and self-serve offerings. The prospects from the upcoming releases are where things get interesting. Wicked for Good, Avatar: Fire & Ash, Zootopia, and Tron Ares are just a few movies that are anticipated to drive box office reacceleration.

With demand recovery across both national and local advertising channels, National CineMedia, Inc. (NASDAQ:NCMI) is forecasted to return approximately 50% in one year, according to estimates by Yahoo Finance analysts.

National CineMedia, Inc. (NASDAQ:NCMI), headquartered in Colorado, is a cinema advertising network in North America. Founded in 2006, the company, along with its subsidiaries, sells advertising to businesses and operates third-party theater circuits.

4. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)

Upside potential as of August 16, 2025: 76.25%

Catherine Novack, an analyst at JonesTrading, has raised the price target on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to $9.00 from $6.00, while reaffirming a Buy rating on the stock. This potential upside of about 66.98% from the current price reflects the company’s strong position following FDA approval of its NDA resubmission.

Earlier on July 17, 2025, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s resubmitted New Drug Application (NDA) for its lead product, Reproxalap, aimed at the ophthalmic disorder dry eye disease. The regulatory authority has set December 16, 2025, as the target action date under the Prescription Drug User Fee Act (PDUFA) for completing its review.

This is when things get interesting. AbbVie is anticipated to pay $100 million upfront and share US profits if the approval is granted, which many believe will mitigate the risks associated with commercialization. The platform offered by Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) also includes follow-on assets like ADX-629 and ADX-2191.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a Massachusetts-based biotechnology company that engages in solutions aimed at immune-mediated and metabolic diseases. Incorporated in 2004, the company is committed to enhancing the patient’s well-being.

3. Arvinas, Inc. (NASDAQ:ARVN)

Upside potential as of August 16, 2025: 160.10%

XTX Topco Ltd has increased its stake in Arvinas, Inc. (NASDAQ:ARVN) by 194.2% during the first quarter, as disclosed in the company’s recent disclosure with the Securities & Exchange Commission. With the purchase of 51,658 shares, the firm now holds 78,257 shares of the company’s stock, valued at $549,000.

Arvinas, Inc. (NASDAQ:ARVN) recently achieved a milestone in its partnership with Pfizer to co-develop Vepdegestrant. The U.S. FDA is set to review the marketing application for the drug that is targeted at people with advanced or metastatic breast cancer who have previously received endocrine-based therapy. With a target action date of June 5, 2026, the solution is to address the unmet medical needs.

Considering the company’s robust balance sheet, management is confident in its resources to advance its exciting programs. Arvinas, Inc. (NASDAQ:ARVN) has prominent clinical and regulatory programs across its pipeline of PROTAC degraders, and that’s what makes it so compelling.

Arvinas, Inc. (NASDAQ:ARVN) is a Connecticut-based clinical-stage biotechnology company that engages in solutions to degrade disease-causing proteins. Founded in 2013, the company focuses on PROTAC (PROteolysis TArgeting Chimera) technology to power the body’s natural systems.

2. Savara Inc. (NASDAQ:SVRA)

Upside potential as of August 16, 2025: 174.34%

H.C. Wainwright has raised the price target on Savara Inc. (NASDAQ:SVRA) to $5.00 from $2.00, while upgrading the stock from Neutral to Buy. Much of this optimism is driven by the company’s agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) data requirements.

During a Type A meeting, Savara Inc. (NASDAQ:SVRA) resubmitted a Biologics License Application (BLA) for Molbreevi, after being refused a File letter from the agency. Andrew Fein, an analyst at H.C. Wainwright, sees improved results for the company’s BLA, which is set to be resubmitted in December.

Replacing the previous drug substance manufacturer, GEMA Biotech, the filing now includes Fujifilm Diosynth Biotechnologies. Many believe it to be a “make it or break it” event, and certainly, the company now appears poised to make it.

Savara Inc. (NASDAQ: SVRA) is a clinical-stage biopharmaceutical company based in Pennsylvania that provides solutions for rare respiratory diseases. Founded in 2007, the company is committed to developing innovative therapies to improve the lives of many.

1. Ovid Therapeutics Inc. (NASDAQ:OVID)

Upside potential as of August 16, 2025: 250.52%

Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a Buy rating and a price target of $5.50, reflecting a potential surge of nearly 467% from the current price.

Much of this optimism surrounds the company’s OV329, which is anticipated to achieve $1 billion in sales in the U.S. alone, five years after its launch. With a focus on treating epilepsy and seizure-related neurological disorders, Ovid Therapeutics Inc. (NASDAQ:OVID) establishes a strong foundation in the market that is expected to continue growing.

Additionally, Ovid Therapeutics Inc. (NASDAQ:OVID) is developing KCC2 activators that are critical chloride pumps enabling neurons to control excessive electrical activity. This means that through these activators, the company can target multiple diseases in an attempt to open the door to transformative therapies that have both clinical and market prospects.

Ovid Therapeutics Inc. (NASDAQ:OVID) is a New York-based biopharmaceutical company that provides solutions for people suffering from epilepsies and seizure-associated neurological disorders. Incorporated in 2014, the company is committed to improving each day for its patients.

While we acknowledge the potential of OVID to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OVID and that has 100x upside potential, check out our report about this cheapest AI stock.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Headline NASDAQ:DH NASDAQ:ARVN NASDAQ:SVRA NASDAQ:SHLS Show more...

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Insider Monkey Ads

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returns! Sign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on this $3 stock with 400% upside potential.
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

8 Best US Stocks Under $10 to Invest in

Published on August 21, 2025 at 2:23 pm by Rameen Kasana in Hedge Funds, News

Our Methodology

8. Definitive Healthcare Corp. (NASDAQ:DH)

7. Evolv Technologies Holdings, Inc. (NASDAQ:EVLV)

6. Shoals Technologies Group, Inc. (NASDAQ:SHLS)

5. National CineMedia, Inc. (NASDAQ:NCMI)

4. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)

3. Arvinas, Inc. (NASDAQ:ARVN)

2. Savara Inc. (NASDAQ:SVRA)

1. Ovid Therapeutics Inc. (NASDAQ:OVID)

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

8 Best US Stocks Under $10 to Invest in

Published on August 21, 2025 at 2:23 pm by Rameen Kasana in Hedge Funds, News

Share

Our Methodology

8. Definitive Healthcare Corp. (NASDAQ:DH)

7. Evolv Technologies Holdings, Inc. (NASDAQ:EVLV)

6. Shoals Technologies Group, Inc. (NASDAQ:SHLS)

5. National CineMedia, Inc. (NASDAQ:NCMI)

4. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)

3. Arvinas, Inc. (NASDAQ:ARVN)

2. Savara Inc. (NASDAQ:SVRA)

1. Ovid Therapeutics Inc. (NASDAQ:OVID)

Subscribe to Insider Monkey's Free Daily Newsletter and Join 80K+ Readers

Share

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up: